Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pimavanserin - ACADIA Pharmaceuticals

Next Previous
Drug Profile

Pimavanserin - ACADIA Pharmaceuticals

Alternative Names: ACP-103; BVF-048; Nuplazid; Pimavanserin tartrate

Latest Information Update: 16 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Amides; Antidepressants; Antiparkinsonians; Antipsychotics; Behavioural disorder therapies; Fluorinated hydrocarbons; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Serotonin 2A receptor inverse agonists; Serotonin 5-HT2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Psychotic disorders
  • Phase III Major depressive disorder
  • Phase II Agitation; Insomnia
  • Suspended Schizophrenia
  • No development reported Psychiatric disorders
  • Discontinued Behavioural disorders; Drug-induced akathisia; Drug-induced dyskinesia

Most Recent Events

  • 09 Jun 2025 US Court of Appeals for the Federal Circuit rules for patent infringement and validity litigation filed against Aurobindo Pharma by ACADIA Pharmaceuticals for Composition of Matter in the US
  • 16 May 2025 US District Court accepts patent litigation filed against Acadia for 721 formulation patent for NUPLAZID®
  • 07 Mar 2025 Discontinued - Phase-II for Behavioural disorders in Spain (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top